Also found in: Dictionary, Wikipedia.
Related to eprosartan: eprosartan mesylate


an angiotensin II antagonist that causes vasodilation and decreases the effects of aldosterone; used as an antihypertensive, administered orally.


(ep-roe-sar-tan) ,


(trade name)


Therapeutic: antihypertensives
Pharmacologic: angiotensin ii receptor antagonists
Pregnancy Category: D


Alone or with other agents in the management of hypertension.


Blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II at various receptor sites, including vascular smooth muscle and the adrenal glands.

Therapeutic effects

Lowering of BP in patients with hypertension.


Absorption: 13% absorbed following oral administration.
Distribution: Crosses the placenta.
Protein Binding: 98%.
Metabolism and Excretion: Excreted mostly unchanged in feces via biliary excretion.
Half-life: 20 hr.

Time/action profile (antihypertensive effect with chronic dosing)

POwithin 1–2 hr2–3 wksr24 hr


Contraindicated in: Hypersensitivity; Concurrent use with aliskiren in patients with diabetes or moderate-to-severe renal impairment (CCr <60 mL/min) Obstetric: Can cause injury or death of fetus – if pregnancy occurs, discontinue immediately. Lactation: Discontinue drug or use formula.
Use Cautiously in: Volume- or salt-depleted patients or patients receiving large doses of diuretics (correct deficits before initiating therapy); genetic implication Black patients (may not be as effective); Impaired renal function caused by primary renal disease or heart failure (may worsen renal function); Women of childbearing potential; Pediatric: Safety not established.

Adverse Reactions/Side Effects

Central nervous system

  • depression
  • fatigue


  • hypotension

Ear, Eye, Nose, Throat

  • pharyngitis
  • rhinitis

Fluid and Electrolyte

  • hyperkalemia


  • abdominal pain


  • impaired renal function


  • pain


  • angioedema (life-threatening)


Drug-Drug interaction

Additive hypotension with other antihypertensives.Excessive hypotension may occur with concurrent use of diuretics.↑ risk of hyperkalemia with concurrent use of potassium supplements,potassium-containing salt substitutes, or potassium-sparing diuretics.↑ risk of hyperkalemia, renal dysfunction, hypotension, and syncope with concurrent use of ACE inhibitors or aliskiren ; avoid concurrent use with aliskiren in patients with diabetes or CCr <60 mL/minNSAIDs and selective COX-2 inhibitors may blunt the antihypertensive effect and ↑ the risk of renal dysfunction.


Oral (Adults) 600 mg once daily when used as monotherapy in patients who are not volume depleted; may be ↑ to 800 mg/day (in 1–2 divided doses).

Renal Impairment

Oral (Adults) CCr <60 mL/min—Do not exceed 600 mg/day.

Availability (generic available)

Tablets: 400 mg, 600 mg
In combination with: hydrochlorothiazide (Teveten HCT; see combination drugs).

Nursing implications

Nursing assessment

  • Assess BP (lying, sitting, standing) and pulse frequently during initial dosage adjustment and periodically throughout therapy. Notify health care professional of significant changes.
  • Monitor frequency of prescription refills to determine compliance.
  • Assess patients for signs of angioedema (dyspnea, facial swelling). May rarely cause angioedema.
  • Lab Test Considerations: Monitor renal function. May cause increase in BUN and serum creatinine.
    • May cause hyperkalemia.
    • May cause elevated AST, ALT, and alkaline phosphatase.
    • May cause slight decrease in hemoglobin, neutropenia, or thrombocytopenia.

Potential Nursing Diagnoses

Risk for injury (Adverse Reactions)
Noncompliance (Patient/Family Teaching)


  • Volume depletion should be corrected, if possible, before initiation of therapy.
  • Oral: May be administered without regard to meals.

Patient/Family Teaching

  • Emphasize the importance of continuing to take as directed, even if feeling well. Take missed doses as soon as remembered if not almost time for next dose; do not double doses. Instruct patient to take medication at the same time each day. Warn patient not to discontinue therapy unless directed by health care professional.
  • Caution patient to avoid salt substitutes containing potassium or foods containing high levels of potassium or sodium unless directed by health care professional. See.
  • Encourage patient to comply with additional interventions for hypertension (weight reduction, low-sodium diet, discontinuation of smoking, moderation of alcohol consumption, regular exercise, stress management). Medication controls but does not cure hypertension.
  • Instruct patient and family on proper technique for monitoring BP. Advise them to check BP at least weekly and to report significant changes.
  • Caution patient to avoid sudden changes in position to decrease orthostatic hypotension. Use of alcohol, standing for long periods, exercising, and hot weather may increase orthostatic hypotension.
  • May cause dizziness. Caution patient to avoid driving or other activities requiring alertness until response to medication is known.
  • Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications, especially cough, cold, or allergy remedies.
  • Instruct patient to notify health care professional of medication regimen before treatment or surgery.
  • Instruct patient to notify health care professional if swelling of face, eyes, lips, or tongue or if difficulty swallowing or breathing occur.
  • Advise women of childbearing age to use contraception and notify health care professional if pregnancy is suspected or planned, or if breastfeeding. If pregnancy is detected, discontinue medication as soon as possible. Avoid breastfeeding.
  • Emphasize the importance of follow-up exams to evaluate effectiveness of medication.

Evaluation/Desired Outcomes

  • Decrease in BP without appearance of excessive side effects.


/ep·ro·sar·tan/ (ep″ro-sar´tan) an angiotensin II antagonist used as the mesylate salt as an antihypertensive.


an angiotensin II antagonist that causes vasodilatation and decreases the effects of aldosterone, used as an antihypertensive, administered orally.
References in periodicals archive ?
Teveten(R) HCT is a combination of the angiotensin II receptor blocker (ARB), eprosartan mesylate, and the diuretic, hydrochlorothiazide.
Pharmacokinetic parameters of angiotensin II receptor blockers * Active Bioavail Food Drug metab (%) effect Losartan Yes 33 No Valsartan No 25 Yes Irbesartan No 70 No Candesartan Yes 42 No Telmisartan No 43 No Eprosartan No 15 No Olmesartan Yes 26 No Half-life (hrs) Drug Drug Metab Losartan 2 6-9 Valsartan 9 -- Irbesartan 11-15 -- Candesartan 3.
1) MOrbidity and mortality after Stroke - Eprosartan compared with nitrendipine for Secondary prevention.
Teveten HCT, launched in 2003, combines eprosartan with a diuretic (HCT), providing double-digit reductions in systolic blood pressure.
Examples include valsartan, irbesartan, candesartan, losartan, telmisartan, and eprosartan.
In addition, development efforts continue for novel formulations of several products, including venlafaxine, bupropion, zolpidem, eprosartan, enalapril, and metoprolol, including combination products with application in cardiovascular medicine and metabolic diseases.
The results of the MOSES(1) study (Morbidity and Mortality After Stroke - Eprosartan Compared with Nitrendipine in Secondary Prevention) in more than 1,400 patients were released late Monday at the European Society of Cardiology Congress in Munich.
In the case of the approved angiotensin II inhibitor Eprosartan, he played a key role in development from IND through to NDA.
Biovail Corporation (NYSE:BVF)(TSX:BVF) announced today it has acquired the rights to a novel formulation of eprosartan (Teveten(R)) and a formulation for an enhanced version of carvedilol (Coreg(R)) through the acquisition of the remaining interest in BNC-PHARMAPASS, LLC.
Food and Drug Administration (FDA) for a TEVETEN/HCTZ combination tablet-600 milligrams (mg) of the angiotensin II receptor blocker, eprosartan mesylate (TEVETEN) with 12.
open-house-contracts" for the active pharmaceutical ingredients calcipotriol, duloxetine, eprosartan and eprosartan / hydrochlorothiazide.
The most commonly prescribed drugs in the CCB class are amlodipine and lercanidipine, while the leading ARBs are telmisartan, candesartan, olmesartan, irbesartan, losartan, valsartan, azilsartan medoxomil, and eprosartan.